Accessing hidden
biological processes


Controlling GPCRs
to harness our own biology to treat disease

The potential of GPCR drugs
remains untapped

GPCRs are proven drug targets with
high untapped potential

GPCRs regulate biology

G-protein coupled receptors (GPCRs) are membrane proteins that make cells respond to chemical signals like hormones.

Controlling GPCRs with drugs can treat diseases

Tuning GPCR activities up or down can use our body's cellular activities to treat diseases. That's why 30% of all approved drugs target GPCRs.

Most GPCRs remain uncontrollable by drugs

75% of the 400 GPCRs remain undrugged. Many control important disease-treating biological programs.

Problems with conventional
drug development for many GPCRs

Off-target toxicity
Small molecules often have off-target activity for structurally similar GPCRs, leading to side effects.

Metabolic toxicity
Small molecules can also be processed by the body to yield toxic metabolites.

Lack of efficacy
Small molecules often cannot be found to affect the activity of a GPCR of interest, such as targets that normally respond to large protein-based signals.

Current antibody drugs are safer,
but only inactivate GPCRs

Naturally strong binders that inactivate
Nature evolved antibodies as our body's own drugs to selectively and potently inactivate pathogens.

Proven drugs, but rare for GPCRs
7 of the top 10-selling drugs are engineered antibodies.
However, out of 100 antibody drugs, only 2 target GPCRs.

Antibody GPCRs drugs limited to blockers until now
It's hard enough finding a GPCR blocker. It's hard to bind a GPCR in just the right way to activate it.

There is not a single antibody GPCR activator drug approved or in clinical trials.

We go beyond inhibiting
and find GPCR activating antibodies

FAST finds functional antibodies that have the full range of GPCR control

Abalone Bio's Functional Antibody Selection Technology platform (FAST) combines engineered living cells and data-driven computation to identify antibodies that functionally affect the GPCR target-  including activators.

  • Platform compatible with VHH, scFvs, Fabs
  • Activate small AND large molecule receptors
  • Discover allosteric modulators and antagonists too
  • Cleaner than crosstalk-filled mammalian cell assays
  • Combines experimental and computational

Functional Antibodies tap the hidden therapeutic potential of GPCRs

First therapeutic focus:
Immune system regulators

Neuropathic pain

A hand experiencing neuropathic pain

Inflammatory diseases

Person in pain from an inflammatory disease


Cancer cells

our partners

NSF logo
YCombinator logo
Pioneer Fund logo
Harmonix partners logo
box 1 logo